Caduet Side Effects & Health Impacts

CoQ10 deficiency can present in infancy as a severe encephalomyopathy or multisystemic mitochondrial disease, with features such as hypotonia, developmental delay, intractable seizures, lactic acidosis, cardiomyopathy, and failure to thrive. Reports of infantile‑onset multisystem CoQ10 deficiency describe very early presentations, sometimes in the neonatal period, with rapid neurologic deterioration and involvement of brain, heart, kidney, and liver, and many affected children die in the first months or years of life despite intensive care. The important clinical point is that, although outcomes are often poor in the most severe cases, some infants and young children show neurologic improvement or stabilization when CoQ10 deficiency is recognized early and high‑dose CoQ10 supplementation is started promptly, which is why this diagnosis is considered a treatable cause of infantile encephalomyopathy

Research: Quinzii CM, Hirano M. Coenzyme Q and mitochondrial disease. Dev Disabil Res Rev. 2010;16(2):183-8. Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol. 1997;37(4):212-8. Boitier E, Degoul F, Desguerre I, Charpentier C, François D, Ponsot G, Diry M, Rustin P, Marsac C. A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency. J Neurol Sci. 1998;156(1):41-6. Sobreira C, Hirano M, Shanske S, Keller RK, Haller RG, Davidson E, Santorelli FM, Miranda AF, Bonilla E, Mojon DS, Barreira AA, King MP, DiMauro S. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology. 1997 May;48(5):1238-43.

CoQ10 is a key mitochondrial antioxidant, and circulating levels are often reduced in people with chronic kidney disease and chronic heart failure, where deficiency is linked to greater oxidative stress and poorer organ function. In CKD cohorts, lower CoQ10 levels correlate with increased cardiovascular risk, and supplementation has been reported to improve markers such as proteinuria, mitochondrial function, and oxidative stress, with some studies suggesting better preservation of kidney function over time. In patients with chronic heart failure, trials such as Q-SYMBIO have shown that CoQ10 supplementation can improve cardiac function parameters and significantly reduce major adverse cardiovascular events, cardiovascular mortality, and heart‑failure–related hospitalizations.

Research: Xu Y, Liu J, Han E, Wang Y, Gao J. Efficacy of coenzyme Q10 in patients with chronic kidney disease: protocol for a systematic review. BMJ Open. 2019 May 14;9(5):e029053. Bakhshayeshkaram M, Lankarani KB, Mirhosseini N, Tabrizi R, Akbari M, Dabbaghmanesh MH, Asemi Z. The Effects of Coenzyme Q10 Supplementation on Metabolic Profiles of Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Curr Pharm Des. 2018;24(31):3710-3723. Di Lorenzo A, Iannuzzo G, Parlato A, Cuomo G, Testa C, Coppola M, D'Ambrosio G, Oliviero DA, Sarullo S, Vitale G, Nugara C, Sarullo FM, Giallauria F. Clinical Evidence for Q10 Coenzyme Supplementation in Heart Failure: From Energetics to Functional Improvement. J Clin Med. 2020 Apr 27;9(5):1266. DiNicolantonio JJ, Bhutani J, McCarty MF, O'Keefe JH. Coenzyme Q10 for the treatment of heart failure: a review of the literature. Open Heart. 2015;2:e000326.

Low or depleted magnesium levels are associated with a higher likelihood of several cardiovascular problems, including arrhythmias, where people with low magnesium have been shown to have 2–4 times higher odds of these rhythm disturbances compared with those with normal levels. Low magnesium is also linked to worsening coronary artery disease, progression of heart failure, and development or aggravation of hypertension, driven by disrupted cardiac electrical stability, vascular function, and electrolyte balance. Even mild magnesium depletion may contribute to higher blood pressure over time, adding to the overall cardiovascular burden, especially in individuals with existing heart disease or multiple risk factors.

Research: Kolte D, Vijayaraghavan K, Khera S, Sica DA, Frishman WH. Role of magnesium in cardiovascular diseases. Cardiol Rev. 2014 Jul-Aug;22(4):182-92. Vierling W, Liebscher DH, Micke O, von Ehrlich B, Kisters K. Magnesium deficiency and therapy in cardiac arrhythmias: recommendations of the German Society for Magnesium Research. Dtsch Med Wochenschr. 2013 May;138(22):1165-71. Houston M. The role of magnesium in hypertension and cardiovascular disease. J Clin Hypertens (Greenwich). 2011 Nov;13(11):843-7. Yin Y, Costello RB, Fonarow GC, Heidenreich PA, Morgan CJ, Faselis C, Cheng Y, Zullo AR, Liu S, Lam PH, Rosanoff A, Vargas JD, Gottlieb SS, Deedwania P, Moore HJ, Shao Y, Sheriff HM, Wu WC, Zeng-Treitler Q, Ahmed A. Oral magnesium and outcomes in US veterans with heart failure. Eur Heart J. 2026 Jan 5;47(1):80-90.

CoQ10 deficiency has been identified as a potentially reversible cause of steroid‑resistant nephrotic syndrome and glomerular nephropathy, particularly in children and young adults with genetic defects in CoQ10 biosynthesis. In reported series, affected patients often present with heavy proteinuria and progressive kidney dysfunction that fail to respond to standard steroid therapy, but genetic testing sometimes reveals mutations in CoQ10‑related genes (such as COQ2, COQ6, or ADCK4). The encouraging part is that in a subset of these cases, early and sufficiently dosed CoQ10 supplementation has been associated with reduced proteinuria and stabilization or partial improvement of kidney function, making it an important, treatable consideration in otherwise unexplained steroid‑resistant nephrotic syndrome.

Research: Frehat MQ Sr, Alhadidi A, Almheairat A, Alkhatib L, Al Thaher S, Al Assaf R, Al Qawaqenah M, Mansour B, Khair F. Success of Coenzyme Q10 in Treating Steroid-Resistant Nephrotic Syndrome in Jordan: A Case Series. Cureus. 2025 Apr 30;17(4):e83231. Drovandi S, Lipska-Ziętkiewicz BS, Ozaltin F, et al. Oral Coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary Coenzyme Q10 deficiency. Kidney Int. 2022 Sep;102(3):604-612. Drovandi S, Lipska-Ziętkiewicz BS, et al. Variation of the clinical spectrum and genotype-phenotype associations in Coenzyme Q10 deficiency associated glomerulopathy. Kidney Int. 2022 Sep;102(3):592-603. Salviati L, Sacconi S, Murer L, Zacchello G, Franceschini L, Laverda AM, Basso G, Quinzii C, Angelini C, Hirano M, Naini AB, Navas P, DiMauro S, Montini G. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology. 2005 Aug 23;65(4):606-8.

In some children and young adults, primary CoQ10 deficiency has been linked to hypertrophic cardiomyopathy (HCM), where the heart muscle becomes abnormally thick and stiff despite the absence of more common causes like longstanding hypertension. Case series and reports describe patients with genetically confirmed CoQ10 biosynthetic defects who develop HCM alongside other mitochondrial features such as exercise intolerance, muscle weakness, or neurologic symptoms, and cardiac imaging often shows concentric or asymmetric left ventricular hypertrophy. The hopeful aspect is that early recognition and CoQ10 supplementation have, in some documented cases, led to improved cardiac function or stabilization of wall thickness over time, making CoQ10 deficiency a particularly important and potentially treatable consideration in otherwise unexplained or familial‑appearing HCM.

Research: Adarsh K, Kaur H, Mohan V. Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). Biofactors. 2008;32(1-4):145-9. Sharma A, Fonarow GC, Butler J, Ezekowitz JA, Felker GM. Coenzyme Q10 and Heart Failure: A State-of-the-Art Review. Circ Heart Fail. 2016 Apr;9(4):e002639. Sondheimer N, Hewson S, Cameron JM, Somers GR, Broadbent JD, Ziosi M, Quinzii CM, Naini AB. Novel recessive mutations in COQ4 cause severe infantile cardiomyopathy and encephalopathy associated with CoQ10 deficiency. Mol Genet Metab Rep. 2017 May 11;12:23-27. Smet J, De Meirleir L. Early myoclonic epilepsy, hypertrophic cardiomyopathy and subsequently a nephrotic syndrome in a patient with CoQ10 deficiency caused by mutations in para-hydroxybenzoate-polyprenyl transferase (COQ2). Eur J Paediatr Neurol. 2013 Nov;17(6):625-30.

Low or depleted magnesium levels place people with diabetes and metabolic syndrome (MetSyn) at higher risk of worsening glycemic control and insulin resistance because magnesium is essential for normal glucose metabolism and beta-cell function. When magnesium is low, these metabolic pathways become less efficient, amplifying blood sugar instability, lipid abnormalities, and other MetSyn features. Even moderate depletion can accelerate type 2 diabetes and MetSyn-related complications, underscoring the need for monitoring magnesium status in these vulnerable groups.

Research: Gommers LM, Hoenderop JG, Bindels RJ, de Baaij JH. Hypomagnesemia in Type 2 Diabetes: A Vicious Circle? Diabetes. 2016 Jan;65(1):3-13. Ozcaliskan Ilkay H, Sahin H, Tanriverdi F, Samur G. Association Between Magnesium Status, Dietary Magnesium Intake, and Metabolic Control in Patients with Type 2 Diabetes Mellitus. J Am Coll Nutr. 2019 Jan;38(1):31-39. Mooren FC. Magnesium and disturbances in carbohydrate metabolism. Diabetes Obes Metab. 2015 Sep;17(9):813-23. Paladiya R, Pitliya A, Choudhry AA, Kumar D, Ismail S, Abbas M, Naz S, Kumar B, Jamil A, Fatima A. Association of Low Magnesium Level With Duration and Severity of Type 2 Diabetes. Cureus. 2021 May 27;13(5):e15279. Ju SY, Choi WS, Ock SM, Kim CM, Kim DH. Dietary magnesium intake and metabolic syndrome in the adult population: dose-response meta-analysis and meta-regression. Nutrients. 2014 Dec 22;6(12):6005-19.

Impacted through 2 nutrients: Magnesium, Vitamin D3.

Magnesium depletion can contribute to neurological issues like migraines, depression, seizures, and cognitive impairment by disrupting neuronal excitability, neurotransmitter balance, and NMDA receptor function. Case reports often describe severe symptoms such as tremors, encephalopathy, cerebellar ataxia, or memory problems in affected patients, which typically resolve once magnesium levels are restored. Although these effects occur less frequently than cardiovascular complications, monitoring is advisable particularly in older adults with persistent low magnesium.

Research: Chen F, Wang J, Cheng Y, Li R, Wang Y, Chen Y, Scott T, Tucker KL. Magnesium and Cognitive Health in Adults: A Systematic Review and Meta-Analysis. Adv Nutr. 2024 Aug;15(8):100272. Kumar A, Mehan S, Tiwari A, Khan Z, Gupta GD, Narula AS, Samant R. Magnesium (Mg2+): Essential Mineral for Neuronal Health: From Cellular Biochemistry to Cognitive Health and Behavior Regulation. Curr Pharm Des. 2024;30(39):3074-3107. Varga P, Lehoczki A, Fekete M, Jarecsny T, Kryczyk-Poprawa A, Zábó V, Major D, Fazekas-Pongor V, Csípő T, Varga JT. The Role of Magnesium in Depression, Migraine, Alzheimer's Disease, and Cognitive Health: A Comprehensive Review. Nutrients. 2025 Jul 4;17(13):2216. Mauskop A, Varughese J. Why all migraine patients should be treated with magnesium. J Neural Transm (Vienna). 2012 May;119(5):575-9.

Vitamin D receptors are present in blood vessels and heart muscle, and deficiency has been linked in observational studies to higher rates of hypertension and heart failure. In large cohorts, people with low 25‑hydroxyvitamin D levels more often have elevated blood pressure and show a greater incidence of new‑onset heart failure and cardiovascular events over time, even after adjusting for some traditional risk factors. Clinically, maintaining adequate vitamin D levels is regarded as a simple, proactive way to support healthier vascular tone, blood pressure regulation, and overall cardiovascular resilience.

Research: Karadeniz Y, Özpamuk-Karadeniz F, Ahbab S, Ataoğlu E, Can G. Vitamin D Deficiency Is a Potential Risk for Blood Pressure Elevation and the Development of Hypertension. Medicina (Kaunas). 2021 Nov 25;57(12):1297. Thomas J. Wang, et al. Vitamin D Deficiency and Risk of Cardiovascular Disease. Circulation. 7 January 2008. Volume 117, Number 4. Ajenaghughrure G, Nwaezeapu K, Ogunniyi K. Impact Of Vitamin D Deficiency On Outcomes In Patients With Diastolic Heart Failure Journal of Cardiac Failure, 32360. Valer-Martinez A, Bes-Rastrollo M, Martinez JA, Martinez-Gonzalez MA, Sayon-Orea C. Vitamin D and the Risk of Developing Hypertension in the SUN Project: A Prospective Cohort Study. Nutrients. 2024 Jul 20;16(14):2351.

Vitamin D deficiency has been consistently associated with higher risk of metabolic problems, including insulin resistance and type 2 diabetes. A meta-analysis of 21 prospective studies following 76,220 participants and documenting 4,996 new type 2 diabetes cases found a clear, statistically significant inverse relationship between circulating 25(OH)D levels and future diabetes risk across diverse populations. In clinical research, people with type 2 diabetes typically show significantly lower vitamin D levels and higher HOMA-IR scores than healthy controls, with an inverse correlation between vitamin D status and insulin resistance that supports a potential mechanistic role of deficiency in the pathophysiology of insulin resistance.

Research: Xu, Z., Gong, R., Luo, G. et al. Association between vitamin D3 levels and insulin resistance: a large sample cross-sectional study. Sci Rep 12, 119 (2022). Jain PK, Nigotia P, Mishra A, Singh LP. Association of vitamin D deficiency with insulin resistance among type 2 diabetes mellitus patients - A case-control study. Bioinformation. 2025 Aug 31;21(8):2897-2900. Ehrampoush E, Mirzay Razzaz J, Arjmand H, Ghaemi A, Raeisi Shahraki H, Ebrahim Babaei A, Osati S, Homayounfar R. The association of vitamin D levels and insulin resistance. Clin Nutr ESPEN. 2021 Apr;42:325-332. Song Y, Wang L, Pittas AG, Del Gobbo LC, Zhang C, Manson JE, Hu FB. Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care. 2013 May;36(5):1422-8.

In both children and adults, vitamin E deficiency can contribute to retinopathy and visual impairment because α‑tocopherol serves as a key fat‑soluble antioxidant that protects photoreceptor cells and retinal membranes from cumulative oxidative damage. Clinical reports describe patients with prolonged low vitamin E status developing pigmentary retinopathy, reduced visual acuity, and abnormal electroretinograms, sometimes alongside peripheral neuropathy, which can improve partially when deficiency is identified and corrected. These neurosensory changes appear more frequently in settings of fat malabsorption or genetic disorders affecting vitamin E transport, highlighting the importance of monitoring vitamin E status in at‑risk groups with otherwise unexplained visual decline.

Research: Runge P, Muller DP, McAllister J, Calver D, Lloyd JK, Taylor D. Oral vitamin E supplements can prevent the retinopathy of abetalipoproteinaemia. Br J Ophthalmol. 1986 Mar;70(3):166-73. Pang J, Kiyosawa M, Seko Y, Yokota T, Harino S, Suzuki J. Clinicopathological report of retinitis pigmentosa with vitamin E deficiency caused by mutation of the alpha-tocopherol transfer protein gene. Jpn J Ophthalmol. 2001 Nov-Dec;45(6):672-6. Edwards G, Olson CG, Euritt CP, Koulen P. Molecular Mechanisms Underlying the Therapeutic Role of Vitamin E in Age-Related Macular Degeneration. Front Neurosci. 2022 May 4;16:890021. Ng EY, Chiew Y, Phang SCW, Ng YT, Tan GCJ, et al. (2021) The Effects of Vitamin E on Non-proliferative Diabetic Retinopathy in Type 2 Diabetes Mellitus. Int J Diabetes Clin Res 8:142.

Impaired renal magnesium reabsorption from low or depleted magnesium levels carries a notable association with worse kidney outcomes, shown by adjusted odds ratios of 1.7–3.0 in affected patients. This contributes to electrolyte imbalances and may worsen overall kidney function over time, with studies reporting hypomagnesemia in nearly a quarter of patients who already have impaired renal function. Monitoring renal function and magnesium status remains crucial for at-risk individuals to avert complications such as acute kidney injury or hospitalization.

Research: Ferrè S, Li X, Adams-Huet B, Maalouf NM, Sakhaee K, Toto RD, Moe OW, Neyra JA. Low serum magnesium is associated with faster decline in kidney function: the Dallas Heart Study experience. J Investig Med. 2019 Aug;67(6):987-994.Steven Van Laecke, Wim Van Biesen, Raymond Vanholder, Hypomagnesaemia, the kidney and the vessels, Nephrology Dialysis Transplantation, Volume 27, Issue 11, November 2012, Pages 4003–4010. Sarah Cascaes Alves, Cristiane Damiani Tomasi, Larissa Constantino, Vinícius Giombelli, Roberta Candal, Maria de Lourdes Bristot, Maria Fernanda Topanotti, Emmanuel A. Burdmann, Felipe Dal-Pizzol, Cassiana Mazon Fraga, Cristiane Ritter, Hypomagnesemia as a risk factor for the non-recovery of the renal function in critically ill patients with acute kidney injury, Nephrology Dialysis Transplantation, Volume 28, Issue 4, April 2013, Pages 910–916. Liu Z, Wang R, He M, Kang Y. Hypomagnesemia Is Associated with the Acute Kidney Injury in Traumatic Brain Injury Patients: A Pilot Study. Brain Sci. 2023 Mar 31;13(4):593.

Vitamin D deficiency has been associated with a higher risk and greater disease activity in several autoimmune conditions, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and multiple sclerosis (MS). Observational studies consistently report that patients with these autoimmune diseases are more likely to have low 25‑hydroxyvitamin D levels than healthy controls, and that lower levels often correlate with more frequent flares or higher inflammatory markers. Early interventional research also suggests that improving vitamin D status may help modulate immune function and reduce inflammatory activity, supporting its role as a positive adjunct in autoimmune health.

Research: Rexhepi M, Krasniqi B, Hoti K, Daci A, Rexhepi-Kelmendi B, Krasniqi S. Impact of vitamin D supplementation on disease activity and pain management in rheumatoid arthritis: a randomized double-blinded controlled study. BMC Rheumatol. 2025 Jul 11;9(1):87. Abou-Raya A, Abou-Raya S, Helmii M. The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized placebo-controlled trial. J Rheumatol. 2013 Mar;40(3):265-72. Lima GL, Paupitz J, Aikawa NE, Takayama L, Bonfa E, Pereira RM. Vitamin D Supplementation in Adolescents and Young Adults With Juvenile Systemic Lupus Erythematosus for Improvement in Disease Activity and Fatigue Scores: A Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Care Res (Hoboken). 2016 Jan;68(1):91-8. Hupperts R, Smolders J, Vieth R, Holmøy T, Marhardt K, Schluep M, Killestein J, Barkhof F, Beelke M, Grimaldi LME; SOLAR Study Group. Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a. Neurology. 2019 Nov 12;93(20):e1906-e1916.

CoQ10 deficiency is a recognized cause of progressive cerebellar ataxia with cerebellar atrophy, often beginning in childhood or early adulthood and frequently accompanied by seizures, peripheral neuropathy, and cognitive or psychiatric changes. Case series and larger cohorts show that many patients with primary CoQ10 deficiency have prominent cerebellar atrophy on MRI and mixed neurologic features, and in some reports seizures occurred in roughly one‑third of affected individuals. The hopeful aspect is that, unlike many hereditary ataxias, early and sustained CoQ10 supplementation has led to meaningful improvement or stabilization of gait, strength, and seizure control in a substantial subset of patients, which is why CoQ10 deficiency is emphasized as a treatable cause of cerebellar ataxia that should not be missed.

Research: Lamperti C, Naini A, Hirano M, De Vivo DC, Bertini E, Servidei S, Valeriani M, Lynch D, Banwell B, Berg M, Dubrovsky T, Chiriboga C, Angelini C, Pegoraro E, DiMauro S. Cerebellar ataxia and coenzyme Q10 deficiency. Neurology. 2003 Apr 8;60(7):1206-8. Artuch R, Brea-Calvo G, Briones P, Aracil A, Galván M, Espinós C, Corral J, Volpini V, Ribes A, Andreu AL, Palau F, Sánchez-Alcázar JA, Navas P, Pineda M. Cerebellar ataxia with coenzyme Q10 deficiency: diagnosis and follow-up after coenzyme Q10 supplementation. J Neurol Sci. 2006 Jul 15;246(1-2):153-8. Hirano M, Quinzii C, DiMauro S. Restoring balance to ataxia with coenzyme Q10 deficiency. Journal of the Neurological Sciences, 246, 11-12. Naini A, Lewis VJ, Hirano M, DiMauro S. Primary coenzyme Q10 deficiency and the brain. Biofactors. 2003;18(1-4):145-52.

Magnesium depletion undermines healthy aging by disrupting key hallmarks like mitochondrial dysfunction, chronic inflammation, genomic instability, and autophagy, which impair cellular resilience and multisystem longevity. Even beyond specific risks in cardio, metabolic, renal, bone, and neuro categories, mild hypomagnesemia compounds broader age-related vulnerabilities, accelerating frailty and reduced healthspan in older adults. Observational data and mechanistic studies highlight consistent multisystem impacts in elderly individuals with low magnesium.

Research: de Baaij JH, Hoenderop JG, Bindels RJ. Magnesium in man: implications for health and disease. Physiol Rev. 2015 Jan;95(1):1-46. Dominguez LJ, Veronese N, Barbagallo M. Magnesium and the Hallmarks of Aging. Nutrients. 2024 Feb 9;16(4):496. Barbagallo, M., Dominguez, L.J. (2018). Magnesium Role in Health and Longevity. In: Malavolta, M., Mocchegiani, E. (eds) Trace Elements and Minerals in Health and Longevity. Healthy Ageing and Longevity, vol 8. Springer, Cham. Matek Sarić M, Sorić T, Juko Kasap Ž, Lisica Šikić N, Mavar M, Andruškienė J, Sarić A. Magnesium: Health Effects, Deficiency Burden, and Future Public Health Directions. Nutrients. 2025 Nov 20;17(22):3626.

Magnesium depletion can contribute to obesity through disrupted metabolic signaling, insulin sensitivity, and gut microbiota shifts that favor fat storage. Low magnesium impairs energy homeostasis and promotes low-grade inflammation, potentially worsening weight gain in susceptible individuals, especially those with poor diets. Mechanistic and observational links, though not yet confirmed by large RCTs, support monitoring body composition to address this reversible concern.

Research: Al Shammaa A, Al-Thani A, Al-Kaabi M, Al-Saeed K, Alanazi M, Shi Z. Serum Magnesium is Inversely Associated with Body Composition and Metabolic Syndrome. Diabetes Metab Syndr Obes. 2023 Jan 12;16:95-104. Lu L, Chen C, Yang K, Zhu J, Xun P, Shikany JM, He K. Magnesium intake is inversely associated with risk of obesity in a 30-year prospective follow-up study among American young adults. Eur J Nutr. 2020 Dec;59(8):3745-3753. Oliveira AR, Cruz KJ, Severo JS, Morais JB, Freitas TE, Araújo RS, Marreiro DD. Hypomagnesemia and its relation with chronic low-grade inflammation in obesity. Rev Assoc Med Bras (1992). 2017 Feb;63(2):156-163. Cazzola R, Della Porta M, Piuri G, Maier JA. Magnesium: A Defense Line to Mitigate Inflammation and Oxidative Stress in Adipose Tissue. Antioxidants (Basel). 2024 Jul 24;13(8):893.

Impacted through 2 nutrients: Vitamin D3, Vitamin E.

Vitamin D deficiency has been linked to a higher risk of depression, often showing up as low mood, fatigue, and reduced motivation in both observational and clinical studies. In one interventional study, female patients in particular showed the greatest improvement in their depressive symptoms after three months of vitamin D supplementation. Notably, serum serotonin levels significantly increased from baseline in both male and female patients after supplementation, suggesting a plausible biochemical pathway through which vitamin D may positively influence mood and motivation.

Research: Alghamdi S, Alsulami N, Khoja S, Alsufiani H, Tayeb HO, Tarazi FI. Vitamin D Supplementation Ameliorates Severity of Major Depressive Disorder. J Mol Neurosci. 2020 Feb;70(2):230-235. Putranto R, Setiati S, Nasrun MW, Witjaksono F, Immanuel S, Subekti I, Harimurti K, Siswanto A, Shatri H, Suwarto S, Megantara MA. Effects of cholecalciferol supplementation on depressive symptoms, C-peptide, serotonin, and neurotrophin-3 in type 2 diabetes mellitus: A double-blind, randomized, placebo-controlled trial. Narra J. 2024 Dec;4(3):e134. Penckofer S, Ridosh M, Adams W, Grzesiak M, Woo J, Byrn M, Kouba J, Sheean P, Kordish C, Durazo-Arvizu R, Wallis D, Emanuele MA, Halaris A. Vitamin D Supplementation for the Treatment of Depressive Symptoms in Women with Type 2 Diabetes: A Randomized Clinical Trial. J Diabetes Res. 2022 Mar 3;2022:4090807. Alghamdi S, Alsulami N, Khoja S, Alsufiani H, Tayeb HO, Tarazi FI. Vitamin D Supplementation Ameliorates Severity of Major Depressive Disorder. J Mol Neurosci. 2020 Feb;70(2):230-235.

Vitamin E deficiency can drive a progressive neurologic syndrome, including ataxia, sensory neuropathy, and myelopathy, because α‑tocopherol is a critical fat‑soluble antioxidant that protects neuronal membranes and prevents peroxidation of polyunsaturated fatty acids under oxidative stress. In both children with chronic cholestatic liver disease and adults without obvious fat malabsorption, low vitamin E status has been linked to characteristic large‑fiber sensory axonopathy and other degenerative changes, illustrating that unrecognized deficiency can present with strikingly “neurologic‑first” symptoms. When vitamin E deficiency is identified early, appropriately dosed, bioavailable α‑tocopherol supplementation can stabilize or partially reverse neurologic findings in some patients, underscoring the importance of screening at‑risk groups and not dismissing isolated ataxia or neuropathy as purely genetic or idiopathic.

Research: Sokol RJ, Butler-Simon N, Conner C, Heubi JE, Sinatra FR, Suchy FJ, Heyman MB, Perrault J, Rothbaum RJ, Levy J, et al. Multicenter trial of d-alpha-tocopheryl polyethylene glycol 1000 succinate for treatment of vitamin E deficiency in children with chronic cholestasis. Gastroenterology. 1993 Jun;104(6):1727-35. Bonello M, Ray P. A Case of Ataxia with Isolated Vitamin E Deficiency Initially Diagnosed as Friedreich's Ataxia. Case Rep Neurol Med. 2016;2016:8342653. Agarwal A, Garg D, Srivastava AK. Ataxia with Vitamin E Deficiency: A Never to be Missed Treatable Ataxia. Ann Indian Acad Neurol. 2023 Nov-Dec;26(6):1011-1012. Chan KH, O'Sullivan M, Farouji I, Are G, Slim J. Sensory Axonopathy Associated With Vitamin E Deficiency. Cureus. 2021 Feb 17;13(2):e13389.

Vitamin E deficiency can present as a predominantly neuromuscular picture, in which slowly progressive peripheral neuropathy (often large‑fiber, length‑dependent, and sensory‑predominant) coexists with proximal muscle weakness and myopathy due to ongoing oxidative damage to peripheral nerves and muscle cell membranes. In reported series, patients have developed areflexia, gait instability, distal numbness, and reduced vibration sense along with elevated creatine kinase or myopathic changes on EMG, sometimes after years of unrecognized low vitamin E status rather than an obvious malabsorption syndrome. When deficiency is documented and α‑tocopherol is repleted with an adequately absorbed preparation, some individuals show meaningful improvements in strength, sensory symptoms, and electrophysiologic measures, highlighting that peripheral neuropathy and myopathy attributed to “idiopathic” or purely degenerative causes may in fact be partially reversible when vitamin E deficiency is identified and treated.

Research: Puri, V., Chaudhry, N., Tatke, M. and Prakash, V. (2005), Isolated vitamin E deficiency with demyelinating neuropathy. Muscle Nerve, 32: 230-235. Martinello F, Fardin P, Ottina M, Ricchieri GL, Koenig M, Cavalier L, Trevisan CP. Supplemental therapy in isolated vitamin E deficiency improves the peripheral neuropathy and prevents the progression of ataxia. J Neurol Sci. 1998 Apr 1;156(2):177-9. Hegele RA, Angel A. Arrest of neuropathy and myopathy in abetalipoproteinemia with high-dose vitamin E therapy. Can Med Assoc J. 1985 Jan 1;132(1):41-4. Sokol RJ, Butler-Simon N, Heubi JE, Iannaccone ST, McClung HJ, Accurso F, Hammond K, Heyman M, Sinatra F, Riely C, et al. Vitamin E deficiency neuropathy in children with fat malabsorption. Studies in cystic fibrosis and chronic cholestasis. Ann N Y Acad Sci. 1989;570:156-69.

In high‑risk settings such as prematurity or chronic fat malabsorption, vitamin E deficiency can contribute to hemolytic anemia because α‑tocopherol is a fat‑soluble antioxidant that keeps red blood cell membranes more stable under everyday oxidative stress. By helping prevent damage to the polyunsaturated fatty acids in these membranes, vitamin E lowers the chance that red blood cells will break apart too early, which can otherwise show up as fatigue, pallor, jaundice, and lab evidence of anemia. In very low birth‑weight infants and in people with long‑standing fat‑absorption problems, spotting low vitamin E levels early and using a well‑absorbed natural Vitamin E supplement can meaningfully reduce hemolysis risk and support healthier hemoglobin levels over time.

Research: Jilani T, Iqbal MP. Does vitamin E have a role in treatment and prevention of anemia? Pak J Pharm Sci. 2011 Apr;24(2):237-42. Gomez-Pomar E, Hatfield E, Garlitz K, Westgate PM, Bada HS. Vitamin E in the Preterm Infant: A Forgotten Cause of Hemolytic Anemia. Am J Perinatol. 2018 Feb;35(3):305-310. Gross, S., Landaw, S. & Oski, F. The effects of vitamin E on hemolysis in premature infants during the first week of life. Pediatr Res 11, 472 (1977).Jilani T, Iqbal MP. Vitamin E deficiency in South Asian population and the therapeutic use of alpha-tocopherol (Vitamin E) for correction of anemia. Pak J Med Sci. 2018 Nov-Dec;34(6):1571-1575.

In both inherited and acquired deficiency states, vitamin E deficiency can contribute to cerebellar dysfunction and central cognitive effects because α‑tocopherol protects vulnerable neurons, including cerebellar Purkinje cells, from ongoing oxidative damage across the lifespan. In AVED, where an α‑TTP defect prevents normal vitamin E transport, deficiency is associated with spinocerebellar ataxia, Purkinje cell loss, degeneration of sensory neurons, and a characteristic “dying back” neuropathy, yet long‑term α‑tocopherol supplementation over many years can slow or even prevent further neurologic progression when started early. Experimental and clinical data also show that even brief interruptions in vitamin E supplementation can measurably lower plasma total radical‑trapping antioxidant capacity before obvious symptom worsening, highlighting renewed oxidative vulnerability of nervous tissue and reinforcing the importance of consistent repletion to support normal neurogenesis and central nervous system function.

Research: Thapa S, Shah S, Chand S, Sah SK, Gyawali P, Paudel S, Khanal P. Ataxia due to vitamin E deficiency: A case report and updated review. Clin Case Rep. 2022 Sep 6;10(9):e6303. Schuelke M, Finckh B, Sistermans EA, Ausems MG, Hübner C, von Moers A. Ataxia with vitamin E deficiency: biochemical effects of malcompliance with vitamin E therapy. Neurology. 2000 Nov 28;55(10):1584-6. N. Stojiljkovic, S. Redko, F. Gupta, S. Kathiresu Nageshwaran, W. Tse. Cerebellar ataxia due to vitamin E deficiency [abstract]. Mov Disord. 2023; 38 (suppl 1). Traber MG. Vitamin E: necessary nutrient for neural development and cognitive function. Proc Nutr Soc. 2021 Aug;80(3):319-326.

In some adolescents and adults, CoQ10 deficiency presents as an isolated mitochondrial myopathy with exercise intolerance, early fatigue, and proximal muscle weakness rather than a full multisystem syndrome. Muscle biopsies in these patients often show reduced CoQ10 content and ragged‑red fibers or other mitochondrial changes, even when brain, heart, and kidneys appear largely spared on standard evaluation. The encouraging piece is that many individuals with CoQ10‑deficient myopathy experience noticeable improvements in exercise capacity, muscle strength, and CK levels after several months of adequately dosed CoQ10 supplementation, highlighting the importance of recognizing this treatable cause of mitochondrial muscle disease early.

Research: Lalani SR, Vladutiu GD, Plunkett K, Lotze TE, Adesina AM, Scaglia F. Isolated Mitochondrial Myopathy Associated With Muscle Coenzyme Q10 Deficiency. Arch Neurol. 2005;62(2):317–320. Neergheen V, Chalasani A, Wainwright L, et al. Coenzyme Q10 in the Treatment of Mitochondrial Disease. Journal of Inborn Errors of Metabolism and Screening. 2017;5Sacconi S, Trevisson E, Salviati L, Aymé S, Rigal O, Redondo AG, Mancuso M, Siciliano G, Tonin P, Angelini C, Auré K, Lombès A, Desnuelle C. Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul Disord. 2010 Jan;20(1):44-8. Quinzii CM, Hirano M. Coenzyme Q and mitochondrial disease. Dev Disabil Res Rev. 2010;16(2):183-8.

Vitamin D plays a key role in muscle function, so deficiency can present with proximal muscle weakness, diffuse aches, and an increased risk of falls and difficulty rising from a chair or climbing stairs. Clinical reports describe patients with severe vitamin D deficiency and myopathy who regained normal muscle strength and mobility within about 4–6 weeks of treatment; in one series, four patients became fully mobile with normalized 25‑hydroxyvitamin D levels, and a fifth also became mobile even though parathyroid hormone levels, while lower, remained somewhat elevated. The practical takeaway is that, in people with otherwise unexplained muscle weakness, falls, and chronic musculoskeletal pain, checking and correcting vitamin D deficiency can lead to rapid, meaningful improvements in function and quality of life.

Research: Prabhala A, Garg R, Dandona P. Severe myopathy associated with vitamin D deficiency in western New York. Arch Intern Med. 2000 Apr 24;160(8):1199-203. Appel LJ, Michos ED, Mitchell CM, Blackford AL, Sternberg AL, Miller ER 3rd, Juraschek SP, Schrack JA, Szanton SL, Charleston J, Minotti M, Baksh SN, Christenson RH, Coresh J, Drye LT, Guralnik JM, Kalyani RR, Plante TB, Shade DM, Roth DL, Tonascia J; STURDY Collaborative Research Group. The Effects of Four Doses of Vitamin D Supplements on Falls in Older Adults : A Response-Adaptive, Randomized Clinical Trial. Ann Intern Med. 2021 Feb;174(2):145-156. Borim FSA, Alexandre TDS, Neri AL, Máximo RO, Silva MF, de Oliveira C. Combined Effect of Dynapenia (Muscle Weakness) and Low Vitamin D Status on Incident Disability. J Am Med Dir Assoc. 2019 Jan;20(1):47-52. Lois Baker. UB Endocrinologist Reports First U.S. Cases Of Severe Muscle Weakness Due To Vitamin D Deficiency. University of Buffalo. April 2000.

In the gums and supporting tissues around the teeth, low CoQ10 levels have been linked to worse periodontal inflammation and deeper pocketing, likely because CoQ10 is essential for local mitochondrial energy production and antioxidant defense. Small human studies have found that people with periodontitis often have reduced CoQ10 in gingival tissue or crevicular fluid, and that topical or oral CoQ10 used alongside standard scaling and root planing can modestly improve measures such as bleeding on probing and pocket depth. The practical implication is that maintaining adequate CoQ10 status may help support healthier periodontal tissues and could be a useful adjunctive strategy, particularly in individuals with chronic gum disease or high oxidative stress in the oral cavity.

Research: Prakash S, Sunitha J, Hans M. Role of coenzyme Q(10) as an antioxidant and bioenergizer in periodontal diseases. Indian J Pharmacol. 2010 Dec;42(6):334-7. R. Nakamura, G.P. Littarru, K. Folkers, & E.G. Wilkinson. Study of CoQ10-Enzymes in Gingiva from Patients with Periodontal Disease and Evidence for a Deficiency of Coenzyme Q10*, Proc. Natl. Acad. Sci. U.S.A. 71 (4) 1456-1460. Ali K. Barakat et.al. Clinical Evaluation of Co-enzyme Q10 in Management of Chronic Periodontitis Patients: Mouth Split Study. International Journal of Health Sciences & Research. Vol.9; Issue: 1; January 2019.

In fat‑malabsorption states and cholestatic liver disease, vitamin E deficiency can amplify oxidative injury because α‑tocopherol is normally carried on circulating lipoproteins and helps shield both cell membranes and lipids from ongoing free‑radical damage. In severe genetic fat‑malabsorption such as abetalipoproteinemia, very low plasma vitamin E levels have been linked to progressive ophthalmopathy and neuropathy, and even with aggressive supplementation, HDL particles can remain severely oxidized, signaling persistent lipid peroxidation and oxidative modification of lipoproteins. Together, these observations support the idea that vitamin E deficiency layered on top of structurally abnormal or depleted lipoproteins creates a “perfect storm” for heightened oxidative stress in tissues, underscoring the need for early detection, carefully absorbed α‑tocopherol formulations, and close monitoring of at‑risk patients with chronic cholestasis or malabsorption.

Research: Burnett JR, Hooper AJ. Vitamin E and oxidative stress in abetalipoproteinemia and familial hypobetalipoproteinemia. Free Radic Biol Med. 2015 Nov;88(Pt A):59-62. Siener R, Machaka I, Alteheld B, Bitterlich N, Metzner C. Effect of Fat-Soluble Vitamins A, D, E and K on Vitamin Status and Metabolic Profile in Patients with Fat Malabsorption with and without Urolithiasis. Nutrients. 2020 Oct 12;12(10):3110. Margareth L. G. SaronI, et al. Nutritional status of patients with biliary atresia and autoimmune hepatitis related to serum levels of vitamins A, D and E. Department of Pediatrics. UNICAMP, Campinas, SP, Brazil 2008. Granot E, Kohen R. Oxidative stress in abetalipoproteinemia patients receiving long-term vitamin E and vitamin A supplementation. Am J Clin Nutr. 2004 Feb;79(2):226-30.